Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Immunome, Inc. (IMNM : NSDQ)
 
 • Company Description   
Immunome, Inc. is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome, Inc. is based in Exton, United States.

Number of Employees: 177

 
 • Price / Volume Information   
Yesterday's Closing Price: $20.90 Daily Weekly Monthly
20 Day Moving Average: 1,287,348 shares
Shares Outstanding: 113.58 (millions)
Market Capitalization: $2,373.78 (millions)
Beta: 2.55
52 Week High: $30.06
52 Week Low: $11.55
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -23.05% -22.80%
12 Week -13.53% -15.53%
Year To Date -2.70% -13.16%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
18702 N. CREEK PARKWAY SUITE 100
-
BOTHELL,WA 98011
USA		 ph: 425-939-7410
fax: -		 investors@immunome.com http://www.immunome.com
 
 • General Corporate Information   
Officers
Clay Siegall - President; Chief Executive Officer and Director
Max Rosett - Chief Financial Officer
Isaac Barchas - Director
Jean-Jacques Bienaime - Director
James Boylan - Director

Peer Information
Immunome, Inc. (CORR.)
Immunome, Inc. (RSPI)
Immunome, Inc. (CGXP)
Immunome, Inc. (BGEN)
Immunome, Inc. (GTBP)
Immunome, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45257U108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/26
Next Expected EPS Date: 11/05/26
Share - Related Items
Shares Outstanding: 113.58
Most Recent Split Date: (:1)
Beta: 2.55
Market Capitalization: $2,373.78 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.65 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.38 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/05/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.51
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -30.00%
vs. Previous Quarter: -35.42%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
09/30/26 - -
06/30/26 - -50.56
03/31/26 - -51.15
ROA
09/30/26 - -
06/30/26 - -46.93
03/31/26 - -47.32
Current Ratio
09/30/26 - -
06/30/26 - 15.08
03/31/26 - 21.68
Quick Ratio
09/30/26 - -
06/30/26 - 15.08
03/31/26 - 21.68
Operating Margin
09/30/26 - -
06/30/26 - -
03/31/26 - -
Net Margin
09/30/26 - -
06/30/26 - -
03/31/26 - -
Pre-Tax Margin
09/30/26 - -
06/30/26 - -
03/31/26 - -5,593.85
Book Value
09/30/26 - -
06/30/26 - 4.64
03/31/26 - 5.20
Inventory Turnover
09/30/26 - -
06/30/26 - -
03/31/26 - -
Debt-to-Equity
09/30/26 - -
06/30/26 - 0.00
03/31/26 - 0.00
Debt-to-Capital
09/30/26 - -
06/30/26 - 0.00
03/31/26 - 0.00
 

Powered by Zacks Investment Research ©